Clearance of levofloxacin by an in vitro model of continuous venovenous hemodialysis (CVVHD).
Information about the elimination and the adequate dosing of levofloxacin during renal replacement therapy is scarce. The aim of this study was to characterize in vitro the elimination of levofloxacin during continuous venovenous hemodialysis (CVVHD) and to investigate whether the CVVHD clearances of creatinine and urea are correlated with the levofloxacin clearance in order to facilitate dosage adjustments. An in vitro model of CVVHD was established using five dialyzer membranes at varying dialysate flow rates applied in the clinical setting (8, 16, 25, 33 and 41 ml/min). Plasma and dialysate samples were drawn for determination of levofloxacin, creatinine and urea concentrations to evaluate clearances by CVVHD. During CVVHD, the clearance of levofloxacin varied between 9.02 and 33.30 ml/min, depending on the chosen setup. Positive correlations (p<0.001) were received for: dialysate flow rate (QD) and creatinine/ urea clearances (R(2)>0.93); QD and levofloxacin clearance (R(2) 0.59-0.71); levofloxacin and creatinine clearance (R(2) 0.69-0.75); and levofloxacin and urea clearance (R(2) 0.56-0.75) as well. When dosing critically ill patients, therefore, extracorporeal as well as total clearance of levofloxacin should be considered.
Siewert
S
S
Institute of Clinical Pharmacology, University of Rostock, Rostock, Germany. Saskia-Siewert@web.de
Drewelow
B
B
Mueller
S C
SC
D000892:Anti-Infective Agents, Urinary / Q000493:pharmacokinetics*; D006801:Humans; D064704:Levofloxacin; D008422:Materials Testing / Q000295:instrumentation / Q000379:methods; D008567:Membranes, Artificial; D015242:Ofloxacin / Q000493:pharmacokinetics*; D006435:Renal Dialysis / Q000295:instrumentation / Q000379:methods*
D000892:Anti-Infective Agents, Urinary; D008567:Membranes, Artificial; D064704:Levofloxacin; D015242:Ofloxacin